Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Holding DNTH?
Track your performance easily
DNTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.58 - $33.77
Previous Close$29.06
Volume168.30K
Average Volume (3M)191.07K
Market Cap
$878.05M
Enterprise Value$597.24M
Total Cash (Recent Filing)$281.12M
Total Debt (Recent Filing)$311.00K
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Mar 20, 2025EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.50
Shares Outstanding29,354,320
10 Day Avg. Volume134,084
30 Day Avg. Volume191,066
Standard Deviation0.23
R-Squared0.17
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)2.38
Price to Sales (P/S)213.14
Price to Cash Flow (P/CF)-15.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue259.67
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.22
Forecast
1Y Price Target
$47.75Price Target Upside64.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Dianthus Therapeutics News
PremiumCompany Announcements
Dianthus Therapeutics Reports Q3 Progress and Financials
PremiumCompany Announcements
Dianthus Therapeutics Appoints Steven Romano to Board
Ownership Overview
29.06% Insiders
17.80% Mutual Funds
0.71% Other Institutional Investors
42.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $6.58 and its highest was $33.77 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Currently, no data Available
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Mar 20, 2025 which is in 130 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.595 by -$0.145.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -$0.75.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 29,366,352 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.595. Following the earnings report the stock price went down -2.809%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Among the largest hedge funds holding Dianthus Therapeutics’s share is Fairmount Funds Management Llc. It holds Dianthus Therapeutics’s shares valued at 72M.
---
Dianthus Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.75 (64.32% Upside)
$47.75 (64.32% Upside)
Blogger Sentiment
Bullish
DNTH Sentiment 66%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 229.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 7.3%
Last 30 Days ▼ 9.4%
Last 30 Days ▼ 9.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
155.58%
12-Months-Change
Fundamentals
Return on Equity
-25.99%
Trailing 12-Months
Asset Growth
84.06%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers platform that focuses on critical areas of transplant medicine. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner in June 2015 and is headquartered in Cambridge, MA.
---
DNTH Stock 12 Month Forecast
Average Price Target
$47.75
▲(64.32% Upside)
Technical Analysis
ALX Oncology Holdings
―
Arcutis Biotherapeutics
―
Black Diamond Therapeutics
―
Cabaletta Bio
―
Best Analysts Covering DNTH
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+9.30%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.30% per trade.
---